SG11201808957UA - Penicillin-g acylases - Google Patents

Penicillin-g acylases

Info

Publication number
SG11201808957UA
SG11201808957UA SG11201808957UA SG11201808957UA SG11201808957UA SG 11201808957U A SG11201808957U A SG 11201808957UA SG 11201808957U A SG11201808957U A SG 11201808957UA SG 11201808957U A SG11201808957U A SG 11201808957UA SG 11201808957U A SG11201808957U A SG 11201808957UA
Authority
SG
Singapore
Prior art keywords
california
penobscot
drive
city
international
Prior art date
Application number
SG11201808957UA
Other languages
English (en)
Inventor
Jovana Nazor
Vesna Mitchell
David Elgart
Katrina Lexa
Nikki Dellas
Robert Orr
Oscar Alvizo
Ravi Garcia
Judy Viduya
Courtney Moffett
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of SG11201808957UA publication Critical patent/SG11201808957UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/84—Penicillin amidase (3.5.1.11)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01011—Penicillin amidase (3.5.1.11), i.e. penicillin-amidohydrolase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201808957UA 2016-05-05 2017-05-05 Penicillin-g acylases SG11201808957UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332103P 2016-05-05 2016-05-05
PCT/US2017/031342 WO2017193022A1 (en) 2016-05-05 2017-05-05 Penicillin-g acylases

Publications (1)

Publication Number Publication Date
SG11201808957UA true SG11201808957UA (en) 2018-11-29

Family

ID=60203339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808957UA SG11201808957UA (en) 2016-05-05 2017-05-05 Penicillin-g acylases

Country Status (12)

Country Link
US (4) US10724025B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452587B1 (cg-RX-API-DMAC7.html)
JP (1) JP7128519B2 (cg-RX-API-DMAC7.html)
KR (1) KR102382489B1 (cg-RX-API-DMAC7.html)
CN (1) CN109715793A (cg-RX-API-DMAC7.html)
AU (1) AU2017260355B2 (cg-RX-API-DMAC7.html)
CA (1) CA3021009A1 (cg-RX-API-DMAC7.html)
DK (1) DK3452587T3 (cg-RX-API-DMAC7.html)
IL (1) IL262550B (cg-RX-API-DMAC7.html)
MX (1) MX389364B (cg-RX-API-DMAC7.html)
SG (1) SG11201808957UA (cg-RX-API-DMAC7.html)
WO (1) WO2017193022A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102382489B1 (ko) 2016-05-05 2022-04-01 코덱시스, 인코포레이티드 페니실린 ｇ 아실라제
EP3645713A4 (en) 2017-06-27 2021-06-30 Codexis, Inc. PENICILLIN-G ACYLASES
CN114760980B (zh) * 2019-09-12 2024-10-18 科德克希思公司 针对10-乙酰基-3,7-二羟基吩噁嗪的过氧化物酶活性

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338400C (en) 1983-08-31 1996-06-18 David H. Gelfand Recombinant fungal cellulases
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CA2191718A1 (en) 1994-06-03 1995-12-14 Randy M. Berka Phosphonyldipeptides useful in the treatment of cardiovascular diseases
ATE294871T1 (de) 1994-06-30 2005-05-15 Novozymes Biotech Inc Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
AU718648B2 (en) * 1996-11-05 2000-04-20 Bristol-Myers Squibb Company Mutant penicillin G acylases
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1717322B1 (en) 1997-01-17 2012-07-18 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
CA2326835A1 (en) 1998-04-02 1999-10-14 Tellus Genetic Resources, Inc. A method for obtaining a plant with a genetic lesion in a gene sequence
CN1314911A (zh) 1998-05-01 2001-09-26 麦克西根股份有限公司 用dna改组优化害虫抗性基因
JP2002517995A (ja) 1998-06-17 2002-06-25 マキシジェン， インコーポレイテッド 所望の特性を有するポリヌクレオチドを生成するための方法
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
EP1104459A1 (en) 1998-08-12 2001-06-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
ATE286136T1 (de) 1998-10-06 2005-01-15 Mark Aaron Emalfarb Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
AU6510799A (en) 1998-10-07 2000-04-26 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
JP2002534965A (ja) 1999-01-19 2002-10-22 マキシジェン， インコーポレイテッド 所望の特徴を有する文字ストリング、ポリヌクレオチドおよびポリペプチドを作製するための方法
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
AR035311A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
SG121902A1 (en) 2000-01-11 2006-05-26 Maxygen Inc Integrated systems for diversity generation and screening
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
AU2001249811B2 (en) 2000-04-03 2006-06-08 Maxygen, Inc. Subtilisin variants
EP2315145B1 (en) 2002-03-01 2015-11-25 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US7629157B2 (en) 2003-08-11 2009-12-08 Codexis, Inc. Ketoreductase polypeptides and related polynucleotides
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
WO2009102901A1 (en) 2008-02-12 2009-08-20 Codexis, Inc. Method of generating an optimized, diverse population of variants
ES2705694T3 (es) 2008-06-13 2019-03-26 Codexis Inc Método de síntesis de variantes de polinucleótidos
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8247192B2 (en) 2008-11-10 2012-08-21 Codexis, Inc. Penicillin-G acylases
WO2013003290A1 (en) 2011-06-28 2013-01-03 Codexis, Inc. Protein variant generation by region shuffling
CN107531762A (zh) 2015-05-07 2018-01-02 科德克希思公司 青霉素g酰化酶
KR102382489B1 (ko) 2016-05-05 2022-04-01 코덱시스, 인코포레이티드 페니실린 ｇ 아실라제

Also Published As

Publication number Publication date
EP3452587B1 (en) 2021-09-08
EP3452587A4 (en) 2020-03-18
IL262550B (en) 2022-05-01
JP7128519B2 (ja) 2022-08-31
EP3452587A1 (en) 2019-03-13
DK3452587T3 (da) 2021-10-11
US20170321202A1 (en) 2017-11-09
MX389364B (es) 2025-03-19
KR20180137025A (ko) 2018-12-26
AU2017260355A1 (en) 2018-11-01
MX2018013259A (es) 2019-04-22
NZ747064A (en) 2025-05-02
WO2017193022A1 (en) 2017-11-09
US11965192B2 (en) 2024-04-23
IL262550A (en) 2018-12-31
AU2017260355B2 (en) 2023-03-30
US11214786B2 (en) 2022-01-04
KR102382489B1 (ko) 2022-04-01
JP2019514395A (ja) 2019-06-06
US20220154164A1 (en) 2022-05-19
US20250034543A1 (en) 2025-01-30
CN109715793A (zh) 2019-05-03
US20200339972A1 (en) 2020-10-29
US10724025B2 (en) 2020-07-28
CA3021009A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
SG11201808176TA (en) Gene therapy for treating mucopolysaccharidosis type ii
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201807998WA (en) Treatment Of Inflammatory Diseases With Inhibitors Of C5a Activity
SG11201908542QA (en) Gip receptor activating peptide
SG11201907846VA (en) Therapeutic rna
SG11201909777YA (en) Modulatory polynucleotides
SG11201909957TA (en) Engineered ligase variants
SG11201908391XA (en) Methods for modulating an immune response
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808812RA (en) Novel aav8 mutant capsids and compositions containing same
SG11201806270XA (en) Gene therapy for treating mucopolysaccharidosis type i
SG11201909949XA (en) Targeted immunotolerance
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201806992VA (en) Antibodies to tigit
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201808709VA (en) T cell receptors
SG11201909856XA (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201810522UA (en) Anti-cd40 antibodies and their uses
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information